Marinus Pharmaceuticals (MRNS) PT Raised to $3 at Jefferies

August 10, 2016 8:28 AM EDT
Get Alerts MRNS Hot Sheet
Price: $1.18 -3.28%

Rating Summary:
    3 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade MRNS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $3.00 (from $2.50).

Abrahams commented, "Though it has taken some time for ganaxolone to find its optimal indications, based on its GABA mechanism, and promising data from SAGE's similar drug allopregnanolone, we continue to believe MRNS's program has good LT promise. With potential initial EEG data for IV ganaxolone in 1H17 and announcement of a strategy in female depression disorders expected 2H16, we see catalysts to drive near-term appreciation."

For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.

Shares of Marinus Pharmaceuticals closed at $1.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment